Drug intelligence / Profile preview

Zijin Prescription

Development stage: Unknown
Lead developer: Shanghai Sixth People’s Hospital
Administration: Oral

Overview

Zijin Prescription is a Traditional Chinese Medicine (TCM) compound developed by the Shanghai Jiao Tong University Affiliated Sixth People's Hospital for the prevention and treatment of COVID-19. It is a hospital-specific herbal formulation designed to manage non-severe cases of SARS-CoV-2 infection. The prescription is typically evaluated as an adjunct to conventional treatment, with clinical outcomes focused on virologic clearance (SARS-CoV-2 nucleic acid testing) and symptom resolution. As a multi-component TCM formula, it is hypothesized to exert therapeutic effects through a combination of broad-spectrum antiviral activity and immunomodulatory properties that help mitigate the inflammatory response associated with COVID-19.

Other names: Zijin FangZijin Formula

Beyond the preview

Go deeper on Zijin Prescription.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zijin Prescription.

Explore the full profile